+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Capricor Therapeutics - logo

Capricor Therapeutics focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 and enderitide, which are in Phase II clinical trials. It is also developing Exosomes for the treatment of cardiovascular and non-cardiovascular diseases. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Technology Growth Opportunities for Exosome-Mediated Drug Delivery - Product Thumbnail Image

Technology Growth Opportunities for Exosome-Mediated Drug Delivery

  • Report
  • September 2022
  • 62 Pages
  • Global
From
The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024 - Product Thumbnail Image

The Global Exosome Market: Size, Forecast, Trials, and Trends, 2024

  • Report
  • September 2024
  • 351 Pages
  • Global
From
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2020 - Product Thumbnail Image

Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 631 Pages
  • Global
From
Exosome Development and Manufacturing Services Market, 2022-2035 - Product Thumbnail Image

Exosome Development and Manufacturing Services Market, 2022-2035

  • Report
  • February 2022
  • 209 Pages
  • Global
From
From
Licensing Deals in Biotechnology 2019-2024 - Product Thumbnail Image

Licensing Deals in Biotechnology 2019-2024

  • Report
  • September 2024
  • 1250 Pages
  • Global
From
From
From
Loading Indicator